ClinicalTrials.gg
Enrolling by invitationNCT07797309PRIV-DRAPEUpdated Sep 1, 2026

Vaginal Examination Drape Supporting Women's Privacy

An interventional study of Privacy-supporting vaginal examination drape in Gynecologic Examination, Pain and Patient Satisfaction, sponsored by KTO Karatay University. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by KTO Karatay University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This single-blind, parallel-group randomised controlled trial evaluates whether a vaginal examination drape designed to support women's privacy reduces pain and improves perceived privacy and examination satisfaction during gynaecological vaginal examination. Women aged 18 and over undergoing vaginal examination at a gynaecology and obstetrics outpatient clinic are randomly allocated 1:1 to an intervention group, in which the privacy-supporting drape is used, or a control group receiving the clinic's routine examination practice. Immediately after the examination, pain (Visual Analogue Scale), examination satisfaction (Gynecologic Examination Satisfaction Scale) and perceived body privacy (Body Privacy in Gynaecology and Obstetrics Scale) are assessed.

Read the detailed description

Background:

Gynaecological and vaginal examinations are core services for protecting and promoting women's sexual and reproductive health and for the early detection of disease. Often described as the most intimate of examinations, the gynaecological assessment is usually performed in the lithotomy position and is frequently experienced as uncomfortable, embarrassing and highly stressful. Being fully exposed and inadequately covered is a major source of anxiety and can lead women to avoid or postpone gynaecological screening. Protecting body privacy is an indispensable part of respectful gynaecological care and is directly related to self-esteem, trust in the health professional and overall satisfaction. Unmet privacy expectations increase state anxiety, which raises muscle tension, reduces examination comfort and intensifies the perception of pain. Standard drapes and gowns leave the genital area exposed for examination while failing to fully protect the privacy of other areas.

Intervention:

A specially designed vaginal examination drape that covers the lower extremities, the pelvic region and the non-examined parts of the body, allowing only the anatomical area to be assessed to be exposed during the procedure by means of a hook-and-loop opening. The drape aims to minimise unnecessary body exposure, help the woman feel in control, encourage muscle relaxation and thereby reduce pain perception and increase examination satisfaction.

Design:

Parallel-group, single-blind, randomised controlled trial reported according to the CONSORT 2025 statement. Participants are allocated 1:1 to the intervention or control group using block randomisation (block size 4, 25 blocks) generated by an independent statistician and concealed in opaque, sealed, sequentially numbered envelopes. Because the drape is visible to participants and providers, participant and provider blinding is not possible; blinding is applied at the data-entry and analysis stages, so the trial is single blind (outcome assessor and data analyst blinded).

Hypotheses:

H1: Women examined with the privacy-supporting drape have lower pain than the control group. H2: Women examined with the drape have higher perceived privacy than the control group. H3: Women examined with the drape have higher examination satisfaction than the control group.

Sample size:

Calculated with G*Power 3.1.9.4 using an independent-samples t test comparing two group means, with an effect size of 0.60, alpha of 0.05 and power of 0.80 at a 1:1 allocation, giving a minimum of 90 women (45 per group). Increasing by 10 percent for possible data loss, 100 women (50 per group) are planned.

Statistical analysis:

Analyses are performed with SPSS 25.0. Group sociodemographic comparability is checked with the chi-square test. Between-group differences in scale scores are assessed with one-way ANOVA or the Kruskal-Wallis H test according to distribution, and mixed-design ANOVA with Bonferroni correction is used for comparisons across measurement times. Significance is set at p less than 0.05 with 95 percent confidence intervals.

Ethics:

Ethics approval will be obtained from the Non-Drug and Non-Medical Device Research Ethics Board of KTO Karatay University Faculty of Medicine, and institutional permission from the participating hospital, before the study begins. The trial is conducted in accordance with the Declaration of Helsinki, and written informed consent is obtained from all participants.

02

Conditions studied

  • Gynecologic Examination
  • Pain
  • Patient Satisfaction
  • Privacy

Keywords

  • Vaginal examination
  • Gynaecological examination
  • Privacy
  • Examination drape
  • Pain
  • Patient satisfaction
  • Women-centred care
  • Randomised controlled trial
03

In context

Pain

10,054 studies on the registry are indexed under Pain; 1,649 are open to participants now.

This study's planned enrollment of 100 is above the median of 66 across 8,493 interventional studies indexed under Pain.

Browse Pain studies →

Lead sponsor

KTO Karatay University is the lead sponsor of 128 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older
  • Undergoing vaginal examination

Exclusion criteria

Exclusion Criteria:

  • Clinical condition requiring emergency obstetric or gynaecological intervention
  • A health problem preventing cognition or communication
  • Diagnosed psychological disorder (depression, post-traumatic stress disorder, bipolar disorder)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Privacy-supporting drape group

    Women undergoing vaginal examination with the privacy-supporting vaginal examination drape, which covers the lower extremities, pelvis and non-examined body parts and exposes only the anatomical area being assessed via a hook-and-loop opening.

    Device: Privacy-supporting vaginal examination drape

  • No intervention
    Control group (routine practice)

    Women undergoing vaginal examination with the clinic's routine examination practice, without the privacy-supporting drape.

Interventions

  • DevicePrivacy-supporting vaginal examination drape

    A specially designed drape used during vaginal examination that covers the lower extremities, pelvic region and non-examined body parts, with a hook-and-loop opening that exposes only the anatomical area being examined, applied during the examination to minimise body exposure and support privacy.

06

What researchers measure

Primary outcomes

  1. Pain during vaginal examination (Visual Analogue Scale, VAS)

    Pain intensity measured on a 10 cm Visual Analogue Scale from 0 (no pain) to 10 (worst pain), completed immediately after the examination. Higher scores indicate greater pain.

    Time frame: Immediately after the vaginal examination (Day 1)

  2. Perceived body privacy (Body Privacy in Gynaecology and Obstetrics Scale)

    Perceived privacy measured with the Body Privacy in Gynaecology and Obstetrics Scale (Degirmen and Sayligil, 2020), a 37-item, 5-point Likert scale with general privacy, rights and privacy, ethics and privacy, and clinical privacy subscales. Higher mean scores indicate greater sensitivity to and protection of privacy.

    Time frame: Immediately after the vaginal examination (Day 1)

  3. Gynaecological examination satisfaction (Gynecologic Examination Satisfaction Scale, GESS)

    Satisfaction measured with the Gynecologic Examination Satisfaction Scale (Muslu, 2026), a 36-item, six-factor scale covering health personnel, examination environment, emotional reactions, menstruation-related concerns, hygiene and privacy. Higher scores indicate greater satisfaction with the gynaecological examination.

    Time frame: Immediately after the vaginal examination (Day 1)

07

Study locations

1 site
  • Osmaniye Training and Research Hospital, Gynaecology and Obstetrics Clinic
    Osmaniye, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Feb 2027, 6 months after the start.

Of 3,731 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 6 months is below that.

Counting every sponsor, half of 3,830 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2026
First posted
Sep 1, 2026
StartActual
Aug 26, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07797309
Responsible party
Aslıhan Turan (Research Assistant, Midwifery, Osmaniye Korkut Ata University) — Principal investigator
First posted
Sep 1, 2026
Start date
Aug 26, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

Aslihan Turan
principal investigator · KTO Karatay University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion